New Treatment Approved for Lung Cancer
KRAS mutations were once thought to be resistant to drug therapy.
Progress Against Cancer
KRAS mutations were once thought to be resistant to drug therapy.
THE FDA GRANTED ACCELERATED APPROVAL TO A NEW THERAPY FOR ADVANCED CERVICAL CANCER The U.S. Food and Drug Administration (FDA) granted accelerated approval to tisotumab vedotin-tftv (Tidvak) for patients with cervical cancer that has...
An immunotherapy combination continues to be effective in treating kidney cancer patients, and more news of the week from Cancer Today.
Blood cancer patients are highly vulnerable to COVID-19 infection. Now mounting evidence suggests they may be also among the least protected by vaccines. Blood Cancer Discovery, a journal of the American Association for Cancer Research (AACR), has recently published studies investigating the...
The FDA approved a tyrosine kinase inhibitor for certain patients with thyroid cancer. The U.S. Food and Drug Administration (FDA) approved cabozantinib (Cabometyx) for adult and pediatric patients 12 years of age and older...
The FDA granted accelerated approval to a new targeted therapeutic and companion diagnostic test for certain adult patients with lung cancer. The U.S. Food and Drug Administration (FDA) granted accelerated approval to mobocertinib (Exkivity)...
THE FDA GRANTED ACCELERATED APPROVAL TO ZANUBRUTINIB FOR CERTAIN ADULTS WITH MARGINAL ZONE LYMPHOMA The U.S. Food and Drug Administration (FDA) granted accelerated approval to zanubrutinib (Brukinsa) for certain adult patients with marginal zone...
9/11 first responders’ cancer survival compares favorably to the general population, and more news of the week from Cancer Today.
Cancer is often described as a disease of old age, but over 15,000 children are diagnosed with cancer each year in the United States. While pediatric cancers tend to have higher survival rates than...
High-poverty counties in the United States may lag far behind wealthier counties in eliminating cervical cancer, a study published in the AACR journal Cancer Epidemiology, Biomarkers & Prevention found.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More